Dr. Siti Idayu Hasan is a Senior Lecturer in the Family Health Discipline at the Department of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya. After completing her PhD, she embarked on a significant journey as a Postdoctoral Research Fellow at UMCAS, collaborating with the International Tobacco Control project team in Canada. Her work focused on measuring the psychosocial and behavioral impact of key national-level policies under the WHO Framework Convention on Tobacco Control (FCTC). She is a Fellow of Hong Kong WHO Collaborating Centre (Tobacco Control) and Committee Member of Scientific Tobacco Working Group (WHO FCTC Malaysia). Continuing her career, Dr. Siti Idayu became the Impact Project Manager at UMCares. In this role, she led the development and management of frameworks to monitor, evaluate, and enhance the effectiveness of community-oriented projects. Her efforts have been pivotal in ensuring that these initiatives bring about meaningful and sustainable improvements in society. Dr. Siti Idayu’s current research themes include tobacco control, mental health, and impact evaluation. Her work in tobacco control encompasses projects like Smoking Cessation, Organizing, Planning, and Execution (SCOPE), Generational Endgame (GEG), and the International Tobacco Control (ITC) project. She is also deeply involved in mental health research, aiming to address and mitigate mental health issues within the community. Beyond her research, Dr. Siti Idayu consults in the expanding field of public health, with a particular focus on tobacco control and mental health. She enjoys engaging with the community through health promotion activities, such as the Generational Endgame initiative, conducted in various settings (i.e. workplace, school and public) to raise awareness and drive positive behavioral change. Dr. Siti Idayu's commitment to improving public health is unwavering. Her work is not just about research and academia; it’s about making a tangible difference in the lives of individuals and communities. She believes that through collaborative efforts and a deep-seated commitment to health promotion, we can create a healthier, more resilient future for everyone. Her journey inspires others to join in the mission of bettering our communities and making impactful contributions to public health.    

As a clinical pharmacist, researcher, and lecturer, my career has been driven by a commitment to improving patient care through translational research and education. With a strong foundation in managing critically ill patients, particularly in infectious diseases, I developed a deep interest in pharmacokinetics and its role in optimizing drug therapy. This passion led me to bridge clinical practice with research, ensuring that scientific advancements translate into real-world benefits for patients. Teaching became a natural extension of this mission, allowing me to shape future pharmacists and researchers with a focus on evidence-based practice and patient-centered care. Today, I continue to integrate clinical expertise, research innovation, and education to advance pharmacy practice and improve health outcomes.

Dr. Nurshamimi was awarded a Malaysia-Imperial Doctoral Programme to study HPV regulation at the Department of Virology, St. Mary’s Campus, Imperial College London, upon graduating with an M.Med.Sc from the University of Malaya in 2008. She joined the Department of Molecular Medicine as a Senior Lecturer in 2014 and was promoted to Associate Professor in 2021. She was a three-time travel award winner for attending HKU-Pasteur workshops at the University of Hong Kong. She also received travel awards from the International Papillomavirus Society in 2017 for the HPV conference in South Africa and a travel award from the EMBL Advanced Training Centre Corporate Partnership Program Fellowship in 2015 for the EMBO Conference in Heidelberg, Germany. She is also a member of the European Association for Cancer Research (EACR) and the European Society for Virology. In 2020, she won the Bill & Melinda Gates Foundation Young Investigator Award for her work on the Chikungunya virus, and in 2022, she received a travel award from Keystone Symposia, Global Health Travel Award, USA. In 2024, she was selected by Cold Spring Harbor Laboratory, USA, to present her work entitled "Morindone from Morinda citrifolia—A promising agent targeting DNA replication and key mutations in colorectal cancer" at their conference 'Mechanisms and Models of Cancer'. Dr. Nurshamimi also holds several patents in the field of anti-aging and colorectal cancer. Her current research is geared toward phase 1 clinical trials for diabetic foot ulcer treatment and investigating potential leads for colorectal cancer targets. She is an Ambassador for Bentham Science Publisher, one of the most renowned ISI publishers in the world. Currently, she is a principal investigator for research projects on colorectal cancer, Zika and dengue viruses, anti-aging, and diabetic foot ulcers.